Pegdinetanib Terminated Phase 2 Trials for Non-Small Cell Lung Carcinoma (NSCLC) Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00850577Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer